GHK-Cu Copper Peptide: Evidence for Skin & Hair

Editorial update and linked-source check: 13 September 2026. This page summarizes selected primary studies and FDA documents; it is not a systematic review or medical advice. See our affiliate disclosure for how the site is funded.

GHK-Cu is the copper complex of the three-amino-acid peptide GHK. Research on a topical serum, a combination containing GHK, and an injectable product answers different questions. The studies below provide limited, product-specific findings; they do not establish broad claims about hair restoration, skin rejuvenation or systemic benefits.

Reading a serum label? Our copper-peptide skincare label guide explains ingredient order, percentage claims and how to check whether a study tested the finished product.

What topical skin studies found

After laser resurfacing: mixed results in a small trial

A 2006 randomized study compared skin-care regimens with and without GHK-Cu after carbon-dioxide laser resurfacing. Thirteen participants completed follow-up. Blinded assessment and computer analysis found no significant between-group advantage in redness resolution, wrinkles or overall skin quality. Patient-reported satisfaction favored the GHK-Cu regimen. These are different outcomes, and both matter when describing the result. A trial this small cannot settle whether other formulations or settings would help. Read Miller and colleagues' study abstract (2006).

Facial wrinkles: a formulation-specific signal

A 2016 split-face study enrolled 40 women, with results reported for 39 after eight weeks. The tested GHK-Cu serum used a lipid-based delivery system. Researchers reported greater reductions in wrinkle volume and depth than with the control serum. The control lacked both GHK-Cu and its delivery system, so the comparison does not isolate the peptide's contribution. The active serum was also always applied to the right side of the face. One participant stopped after skin reactions on both sides. This short study supports further investigation of that formulation; it does not establish that every copper-peptide cream produces the same result. Read Badenhorst and colleagues' paper, shared by an author (2016).

Hair and eyebrow evidence are different

The scalp trial tested a GHK combination

A 2016 randomized, double-blind study enrolled 45 men with pattern hair loss and compared two formulations of ALAVAX with placebo over six months. ALAVAX combined 5-aminolevulinic acid with GHK; it was not a test of standalone GHK-Cu. One active group differed significantly from placebo on a hair-count change measure, while hair length and thickness did not differ significantly between groups. There was no minoxidil comparison arm. This study cannot establish that GHK-Cu matches minoxidil or has fewer side effects. Read Lee and colleagues' original scalp study (2016).

A small eyebrow study reported a positive finding

A 2026 conference-proceedings paper describes a randomized, double-blind comparison in 18 adults with sparse eyebrows. Each person used a GHK-Cu serum on one eyebrow and a matching vehicle on the other for 12 weeks. The authors reported higher hair counts and greater hair diameter on the active side at week 12, with no reported adverse reactions. This is an early finding in a small, selected group. It does not establish effectiveness for scalp pattern hair loss, long-term safety or safety when injected. Read Bo and colleagues' eyebrow study (2026).

Injection evidence and safety

None of the studies summarized above tested subcutaneous GHK-Cu for systemic skin, hair or recovery benefits. Their findings cannot be transferred to injections. In its safety assessment of compounded injectable GHK-Cu, FDA identifies possible unwanted immune responses associated with peptide aggregation and impurities, and says human safety data are limited. Those uncertainties are more specific than simply calling injections an unproven version of a cosmetic. Read FDA's GHK-Cu injection safety statement.

FDA and compounding status depend on the route

FDA's May 14, 2026 update lists GHK-Cu for non-injectable routes in Category 1, meaning it is under evaluation. The document explains that the injectable nomination was withdrawn. Category 1 is not FDA drug approval or final inclusion on the 503A bulks list. The same document announces an intended advisory-committee consultation before the end of February 2027; an intended review is not an approval decision. Read FDA's route-specific update (PDF).

Cosmetic marketing is a separate issue. FDA generally does not approve cosmetics before sale, except for color additives. Products still must meet applicable safety and labeling requirements. Claims to treat disease or affect the body's structure or function can make a product a drug; FDA specifically gives restoring hair growth as an example. Being sold as a serum does not establish approval for a medical claim. FDA's cosmetics oversight explanation and cosmetic-versus-drug guidance explain the distinction.

Our Peptide FDA Status Tracker provides broader context and its own verification dates.

How to read a GHK-Cu claim

• Match the ingredient: GHK alone, GHK-Cu and a multi-ingredient formula are not interchangeable evidence.
• Match the route and condition: eyebrow or facial-skin findings do not establish scalp or injectable benefits.
• Check the outcome: satisfaction, laboratory markers and measured clinical improvement answer different questions.
• Keep the uncertainty visible: small, short studies cannot establish long-term safety or rule out uncommon harms.

Correction, 13 September 2026: The earlier version described a 2015 hair trial and a 2018 comparison with minoxidil without supporting citations. We could not substantiate those descriptions and removed them. This revision links identifiable studies, separates their findings by formulation and use, updates the FDA discussion, and removes the outdated price section and purchasing callout.